Related Experiment Video
Updated: Jan 22, 2026

Identification of Growth Inhibition Phenotypes Induced by Expression of Bacterial Type III Effectors in Yeast
Published on: March 30, 2010
DHRS2 mediates cell growth inhibition induced by Trichothecin in nasopharyngeal carcinoma
Xiangjian Luo1,2,3,4, Namei Li5,6,7, Xu Zhao5,6,7
1Key Laboratory of Carcinogenesis and Invasion, Chinese Ministry of Education, Department of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan, 410078, People's Republic of China. luocsu@hotmail.com.
Background:
Cancer is fundamentally a deregulation of cell growth and proliferation. Cancer cells often have perturbed metabolism that leads to the alteration of metabolic intermediates. Dehydrogenase/reductase member 2 (DHRS2) belongs to short-chain alcohol dehydrogenase/reductase (SDR) superfamily, which is functionally involved in a number of intermediary metabolic processes and in the metabolism of lipid signaling molecules. DHRS2 displays closely association with the inhibition of cell proliferation, migration and quiescence in cancers.
Methods:
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium (MTS), 5-ethynyl-2'-deoxyuridine (EdU) and colony formation assays were applied to evaluate the proliferative ability of nasopharyngeal carcinoma (NPC) cells. We performed lipid metabolite profiling using gas chromatography coupled with mass spectrometry (GC/MS) to identify the proximal metabolite changes linked to DHRS2 overexpression. RNA sequencing technique combined with differentially expressed genes analysis was applied to identify the expression of genes responsible for the anti-tumor effect of trichothecin (TCN), a natural sesquiterpenoid compound isolated from an endophytic fungus.
Results:
Our current findings reveal that DHRS2 affects lipid metabolite profiling to induce cell cycle arrest and growth inhibition in NPC cells. Furthermore, we demonstrate that TCN is able to induce growth inhibition of NPC in vitro and in vivo by up-regulating DHRS2.
Conclusions:
Our report suggests that activating DHRS2 to reprogram lipid homeostasis may be a target for the development of targeted therapies against NPC. Moreover, TCN could be exploited for therapeutic gain against NPC by targeting DHRS2 and it may also be developed as a tool to enhance understanding the biological function of DHRS2.
Insights
Activating Dehydrogenase/reductase member 2 (DHRS2) can inhibit nasopharyngeal carcinoma (NPC) cell growth by altering lipid metabolism. The compound trichothecin (TCN) shows potential therapeutic benefits against NPC by upregulating DHRS2.
Area of Science:
- Oncology
- Metabolomics
- Molecular Biology
Background:
- Cancer is characterized by uncontrolled cell growth and proliferation, often involving altered cellular metabolism.
- Dehydrogenase/reductase member 2 (DHRS2), part of the short-chain alcohol dehydrogenase/reductase (SDR) superfamily, influences intermediary metabolism and lipid signaling.
- DHRS2 expression is associated with inhibited cell proliferation, migration, and quiescence in various cancers.
Purpose of the Study:
- To investigate the role of DHRS2 in nasopharyngeal carcinoma (NPC) cell proliferation and lipid metabolism.
- To identify metabolic changes associated with DHRS2 overexpression in NPC.
- To evaluate the anti-tumor effects of trichothecin (TCN) on NPC by examining its impact on DHRS2 expression.
Main Methods:
- Cell proliferation was assessed using MTS, 5-ethynyl-2'-deoxyuridine (EdU), and colony formation assays.
- Lipid metabolite profiling was performed using gas chromatography-mass spectrometry (GC/MS).
- RNA sequencing and differential gene expression analysis were employed to study TCN's mechanism of action.
Main Results:
- DHRS2 overexpression was found to alter lipid metabolite profiles, leading to cell cycle arrest and growth inhibition in NPC cells.
- Trichothecin (TCN) demonstrated in vitro and in vivo efficacy in inhibiting NPC growth.
- TCN exerts its anti-tumor effects by upregulating DHRS2 expression in NPC.
Conclusions:
- Reprogramming lipid homeostasis through DHRS2 activation presents a potential therapeutic strategy for NPC.
- TCN shows promise as a therapeutic agent for NPC by targeting DHRS2.
- TCN can serve as a valuable tool for further elucidating the biological functions of DHRS2.
Related Concept Videos
Suctioning the Nasopharyngeal Airway
Equipment Required
Feedback Inhibition
Receptor-mediated Endocytosis
Enzyme Inhibition
Primary and Secondary Growth in Roots and Shoots
Cells Coordinate Growth and Proliferation

